Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Adavosertib
Synonyms
Therapy Description

Adavosertib (MK-1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (PMID: 22084170).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Adavosertib MK-1775|AZD1775|AZ1775 WEE1 Inhibitor 4 Adavosertib (MK-1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (PMID: 22084170).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown brain glioma not applicable Adavosertib Preclinical Actionable In a preclinical study, Adavosertib (MK-1775) in combination with radiation, reduced survival of cells derived from pediatric patients with high-grade gliomas (PMID: 24305702). 24305702
Unknown unknown head and neck squamous cell carcinoma not applicable Adavosertib Preclinical Actionable In a preclinical study, Adavosertib (MK-1775) inhibited proliferation in various tumor cell lines, including head and neck squamous cell carcinoma cell lines, in culture (PMID: 23699655). 23699655
Unknown unknown colorectal cancer not applicable Adavosertib Preclinical - Cell line xenograft Actionable In a preclinical study, Adavosertib (MK-1775) inhibited cell proliferation and promoted DNA damage in a human colorectal cancer cell line in culture, and promoted tumor regression in xenograft models (PMID: 23699655). 23699655
ATRX del hepatocellular carcinoma sensitive Adavosertib Preclinical - Cell line xenograft Actionable In a preclinical study, Adavosertib (MK-1775) treatment resulted in cell cycle arrest, DNA damage, and apoptosis in hepatocellular carcinoma cell lines with ATRX gene knocked out via CRISPR-Cas9 in culture, and inhibited tumor growth in cell line xenograft models (PMID: 31551363). 31551363
Unknown unknown lung non-small cell carcinoma not applicable Adavosertib Preclinical - Cell line xenograft Actionable In a preclinical study, Adavosertib (MK-1775) inhibited cell proliferation and promoted DNA damage in human non-small cell lung carcinoma cell lines in culture, and promoted tumor regression in xenograft models (PMID: 23699655). 23699655
Unknown unknown Advanced Solid Tumor not applicable Adavosertib Phase I Actionable In a Phase I trial, Adavosertib (MK-1775) treatment demonstrated safety and preliminary efficacy, resulted in an overall response rate of 3.4% (2/62), a disease control rate of 48.4% (30/62), and a median progression-free survival of 2.7 months in patients with advanced solid tumors (AACR Annual Meeting 2019, Abstract CT022). detail...
Unknown unknown Advanced Solid Tumor not applicable Adavosertib Phase I Actionable In a Phase I trial, Adavosertib (MK-1775) combined with a chemotherapy resulted in a partial response of 10% (17/176) and stable disease in 53% (94/176) of patients with advanced solid tumors (PMID: 27601554). 27601554
Unknown unknown Advanced Solid Tumor not applicable Adavosertib Phase I Actionable In a Phase I trial, Adavosertib (MK-1775) treatment resulted in a partial response in 17% (6/35) and stable disease in 51.4% (18/35) of patients with advanced solid tumors, with a median duration of response of 5.2 months (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825). detail...
ATRX R781* malignant glioma sensitive Adavosertib Preclinical - Patient cell culture Actionable In a preclinical study, Adavosertib (MK-1775) inhibited growth of patient-derived glioma cells harboring ATRX R781* in culture (PMID: 31551363). 31551363
Unknown unknown glioblastoma multiforme not applicable Adavosertib Phase 0 Actionable In a Phase 0 trial, Adavosertib (MK-1775) demonstrated safety and preliminary efficacy, resulted in good brain tumor penetration and Wee1 pathway inhibition in intraoperatively collected tumor samples from patients with first-recurrence glioblastoma (PMID: 29798906). 29798906
NRAS mutant melanoma sensitive Adavosertib Preclinical Actionable In a preclinical study, Adavosertib (MK-1775) showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID: 24791855). 24791855
ATRX S458* malignant glioma sensitive Adavosertib Preclinical - Patient cell culture Actionable In a preclinical study, Adavosertib (MK-1775) inhibited growth of patient-derived glioma cells harboring ATRX S458* in culture (PMID: 31551363). 31551363

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status
NCT01748825 Phase I Adavosertib MK-1775 for Advanced Solid Tumors Completed
NCT02341456 Phase I Adavosertib Carboplatin Paclitaxel Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours Completed
NCT02508246 Phase I Adavosertib Docetaxel Cisplatin AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck Completed
NCT03385655 Phase II Savolitinib Darolutamide Adavosertib Prostate Cancer Biomarker Enrichment and Treatment Selection Recruiting
NCT02087176 Phase II Adavosertib Pegfilgrastim A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer Terminated
NCT02194829 Phase Ib/II Paclitaxel Gemcitabine Adavosertib Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT03284385 Phase II Adavosertib Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 Recruiting
NCT02511795 Phase I Adavosertib Olaparib AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors Completed
NCT02087241 Phase II Adavosertib Carboplatin + Pemetrexed Disodium Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer Terminated
NCT02610075 Phase I Adavosertib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. Completed
NCT01357161 Phase II Carboplatin Adavosertib Paclitaxel A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) Completed
NCT03313557 Phase I Adavosertib AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies Completed
NCT03668340 Phase II Adavosertib A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma Recruiting
NCT02196168 Phase II Adavosertib Cisplatin Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Terminated
NCT02659241 Phase I Adavosertib A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer Recruiting
NCT03333824 Phase I Adavosertib Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer Completed
NCT03253679 Phase II Adavosertib WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Suspended
NCT02465060 Phase II Erdafitinib Copanlisib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Pertuzumab + Trastuzumab Dabrafenib + Trametinib Binimetinib Adavosertib Osimertinib Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Larotrectinib Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT02791919 Phase I Adavosertib Cytarabine + Filgrastim + Fludarabine Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Withdrawn
NCT02666950 Phase II Adavosertib Cytarabine WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
NCT01922076 Phase I Adavosertib WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Active, not recruiting
NCT02513563 Phase II Carboplatin + Paclitaxel Adavosertib AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Recruiting


Additional content available in CKB BOOST